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A B S T R A C T
Background: Relapse prevention strategies include continuation of antidepressant medication and preventive
psychological interventions. This study aims to gain understanding that may inform tailoring of relapse pre-
vention to individual diﬀerences, to improve their eﬀects. Such treatment personalization may be based on
repeated assessments within one individual, using experience sampling methodology. As a ﬁrst step towards
informing decisions based on this methodology, insight is needed in individual diﬀerences in risk of relapse and
response to treatment, and how relapse prevention strategies may diﬀerentially target vulnerability for relapse.
Methods: The smartphone application ‘Imagine your mood’ has been developed speciﬁcally for this study to
assess emotions, imagery, cognitions, and behaviors in daily life. Parallel to the randomized controlled trial
‘Disrupting the rhythm of depression’, 45 remitted recurrently depressed individuals taking continuation anti-
depressant medication will be randomly assigned to either continuing antidepressant medication (n = 15),
continuing antidepressant medication combined with an eight-session preventive cognitive therapy (n = 15), or
tapering of antidepressant medication in combination with preventive cognitive therapy (n = 15). Relapse and
return of depressive symptomatology over a 24-month follow-up will be assessed. Additionally, matched never
depressed individuals (n = 15) will be recruited as controls.
Discussion: This innovative study combines the strengths of a randomized controlled trial and experience sam-
pling methodology in a micro-trial to explore individual diﬀerences in risk of relapse and what works for whom
to prevent relapse. Results may ultimately pave the way for therapists to tailor relapse prevention strategies to
individual (aﬀective) vulnerability.
Trial registration: ISRCTN15472145, retrospectively registered.
1. Introduction
Major Depressive Disorder (MDD) poses a heavy burden on patients
and society [1–3]. The highly recurrent nature of MDD [4,5] adds
greatly to the burden of depression [6,7]. With every previous episode
the risk of relapse increases, so that after having experienced two or
more depressive episodes the chance of relapse is 60–90% [8–10].
Reducing the burden of MDD therefore crucially involves prevention of
recurrence in previously depressed individuals.
Although both continuation of antidepressant medication (ADM)
[11,12] and psychological interventions [13–17] can reduce the risk of
relapse, many previously depressed individuals do relapse in the long
run. Individual patients may diﬀer in their vulnerability for relapse.
Identifying these individual diﬀerences and understanding how dif-
ferent relapse prevention strategies target these vulnerabilities may
enable therapists to further tailor interventions [18]. Crucial questions
therefore seem to be what works best for whom [19,20]. However,
empirical evidence guiding such personalized relapse prevention
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strategies is scarce [21]. To date, attempts to identify single individual
characteristics that determine treatment response have not resulted in
consistent moderators of eﬀect that may inform treatment decisions
[18,22].
Experience sampling method (ESM) [23–25] oﬀers a route towards
personalized interventions [26]. By repeatedly assessing emotions,
cognitions, and behaviors in the ﬂow of daily life, ESM allows for as-
sessment of their interrelations, temporal dynamics and change over
time. Furthermore, integrating ESM in clinical practice may empower
patients [27] and provide feedback to both patients and therapists, with
positive long-term results [28]. Further advantages of ESM are mini-
mization of retrospective biases, which may be particularly relevant in
depression [29], and maximized ecological validity by random sam-
pling in daily life [24]. ESM may be ideally suited for informing and
optimizing personalized treatments [30]. However, for applying ESM to
the individual patient, insight is needed in individual diﬀerences in
vulnerability for relapse and early response to treatment. Also, under-
standing of the working mechanisms of diﬀerent relapse prevention
strategies is needed.
This report aims to describe the theoretical rationale and study
design for ‘Imagine your mood’, an innovative study exploring the po-
tential for using ESM for informing personalized relapse prevention. In
the ‘Imagine your mood’ study, data of both previously depressed and
matched never depressed individuals will be collected. ESM will be
added to a three-arm relapse prevention trial ‘Disrupting the rhythm of
depression’ [31]. This randomized controlled trial (RCT) investigates
PCT while either continuing or tapering ADM as a relapse prevention
strategy compared to continuation ADM in a sample of individuals di-
agnosed with remitted recurrent MDD.
2. Method
2.1. Theoretical rationale
2.1.1. Relapse prevention strategies
Relapse prevention often consists of continuation of antidepressant
medication (ADM) after the acute phase of depression [32]. Meta-
analyses show that ADM reduces risk of relapse [11,12]. However,
many ADM users experience adverse side eﬀects such as weight gain,
sexual problems, and emotional numbing [33,34]. In addition, many
ADM users have diﬃculty with long-term adherence to ADM [35,36].
Discontinuation of ADM may also be problematic as individuals who
wish to discontinue or taper their ADM may be hampered by with-
drawal symptoms [37] and discontinuing their ADM may leave them
more vulnerable to relapse [14,38,39].
Most patients prefer psychological treatment strategies [40,41].
Several psychological interventions have been developed speciﬁcally
for preventing relapse in depression, i.e. preventive cognitive therapy
(PCT) [42], mindfulness-based cognitive therapy (MBCT) [43], and
wellbeing cognitive therapy [44]. Meta-analyses conclude that pre-
ventive psychological therapies reduce risk of relapse [13–17], possibly
even more than continuation of ADM after the acute phase of depres-
sion does [17]. Recently, two randomized controlled trials (RCTs) have
examined whether one of these psychological interventions (MBCT)
may be a viable alternative to continuation of ADM for preventing re-
lapse in depression. These studies show mixed results. Kuyken et al.
[45] found no diﬀerence in relapse rates within 24 months for a group
of remitted recurrently depressed participants that continued ADM
(49%, n = 212) compared to a group that received MBCT with ADM
tapering (44%, n = 212). Huijbers et al. [46], however, found sig-
niﬁcantly higher relapse rates (over 15 months) for the group that re-
ceived MBCT and tapered ADM (54%, n = 128) versus the group that
received MBCT and continued ADM (39%, n = 121).
Thus, although both continuation of ADM [11,12] and psycholo-
gical interventions [13–17] can reduce the risk of relapse, many pre-
viously depressed individuals do relapse in the long run.
2.1.2. Experience sampling methodology
ESM data can be used to model temporal dynamics and individual
networks in accordance with a network perspective on depression. In
this perspective, depression is conceptualized as a complex dynamical
system of interacting symptoms, cognitions, emotions, and behaviors.
Relapse may then be conceptualized as a transition of the network into
a depressive state [47]. Given that depression is highly heterogeneous
[48], these networks may vary greatly between individuals and ESM
may be used to construct personalized networks. These individual
networks potentially contain indicators of vulnerability for relapse,
including early warning signals of relapse within an individual [49].
A body of empirical literature is rapidly emerging that supports the
potential for ESM to contribute to personalizing interventions in de-
pression [30]. First, preliminary studies support the hypothesis that
ESM provides information on vulnerability for relapse. Recently, tem-
poral dynamics of aﬀect have been hypothesized to signal sudden
transitions into and out of a depressive state. Indeed, higher inertia (the
degree to which current states can be predicted from previous states)
was found in individuals at the brink of relapse [49]. Higher inertia of
negative aﬀective in particular is hypothesized to signal relapse [49].
Crucially, increased inertia within an individual may be an early
warning signal of relapse. First evidence of such increased inertia was
demonstrated in a previously depressed individual that attempted to
taper his ADM [50]. The generalizability of this single case study is
limited and requires replication. However, these ﬁndings demonstrate
that individual networks may contain information about vulnerability
for relapse. Further insight is needed in individual diﬀerences in these
vulnerabilities.
Second, ESM allows for in-depth analyses of interrelations between
cognitive mechanisms and aﬀective vulnerabilities for relapse. For ex-
ample, an ESM design was used previously to examine the hypothesis
that the negative aﬀective impact of rumination contributes to de-
pressive symptomatology [51]. Another mechanism of interest is
mental imagery, frequently described as “seeing with the mind's eye”
[52]. Mental imagery has been related to stronger emotional responses
to positive and negative stimuli [53,54]. However, it is unclear how
mental imagery inﬂuences aﬀect dynamics in daily life. Thus, ESM may
elucidate mechanisms that underlie vulnerability for relapse within a
group of previously depressed individuals.
Third, ESM may be used to monitor early responses during diﬀerent
treatment strategies that may predict whether an individual will beneﬁt
from a treatment. The previously mentioned single case study [50]
suggests that ESM may be used to monitor such early responses in in-
dividuals using diﬀerent relapse prevention strategies. In acute de-
pression, early changes in aﬀect were found predictive of treatment
outcome [55]. Aﬀective disturbances may play a central role in the
depressive network [56], given that depression is an emotional disorder
[57]. The importance of aﬀect after remission as a risk factor for de-
pressive relapse is supported by the ﬁnding that mood as assessed using
a one-item visual analogue scale (VAS) running from happy to sad has
been found predictive of relapse [58] even after ﬁve and a half years
[59]. ESM may capitalize on this predictive value of aﬀect, by ex-
amining whether early aﬀective changes indicate whether an individual
will for example be able to successfully taper ADM. However, whether
early aﬀective changes predict treatment outcome of diﬀerent relapse
prevention strategies has not yet been examined.
Fourth, ESM may provide new insights on potential mechanisms by
which treatment strategies prevent depressive relapse. Psychological
interventions and ADM may target vulnerability for relapse in diﬀerent
manners. This was ﬁrst illustrated with ESM data in a study that in-
vestigated the eﬀect of MBCT for individuals with residual depressive
symptomatology. Using ADM during MBCT facilitated decrease in ne-
gative aﬀect, but hampered increase in positive aﬀect [60]. However,
causal inferences based on this study are limited because the use of
ADM was not randomly assigned. This study demonstrates that ESM
may be used for uncovering diﬀerential pathways by which relapse
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prevention strategies may target aﬀect in daily life. These diﬀerential
eﬀects of relapse prevention strategies may ultimately be used for tai-
loring interventions to individual aﬀective vulnerability.
In sum, there are at least four routes to furthering personalized re-
lapse prevention using ESM: exploring individual diﬀerences in vul-
nerability for relapse, examining (cognitive) mechanisms that con-
tribute to (aﬀective) vulnerability, interpreting early changes in
response to treatment, and examining what mechanisms are diﬀeren-
tially targeted by relapse prevention strategies.
2.1.3. Aims and hypotheses
The ﬁrst aim of the ‘Imagine your mood’ study is to explore in-
dividual diﬀerences in vulnerability for future relapse. In addition to
exploring between-individual diﬀerences, within-individual aﬀective
change will be explored as a potential precursor for relapse. It is hy-
pothesized that within-individual increases in negative aﬀect and ne-
gative aﬀective inertia may precede relapse. It will be examined whe-
ther such individual aﬀective trajectories are speciﬁc to individuals at
high risk of depressive relapse by examining these in a never depressed
control group as well. Second, how cognitive mechanisms interact with
aﬀective vulnerability for relapse will be examined. Speciﬁcally, how
mental imagery is related to aﬀect in daily life will be investigated.
Third, it will be examined whether early aﬀective changes may be as-
sociated with successful tapering of ADM. It is hypothesized that af-
fective improvements in the ﬁrst two weeks of tapering may be asso-
ciated with successful tapering of ADM. Fourth, it will be explored how
relapse prevention strategies may diﬀerentially target vulnerability for
relapse by group-based comparison of the networks in the three arms of
the RCT. Finally, several secondary outcome measures will be included
for hypothesis-generating purposes. In sum, this study combines the
strengths of an RCT and ESM in a micro-trial to explore processing of
change during diﬀerent relapse prevention strategies.
3. Study design
This study is designed as a micro-trial that includes ESM to explore
processing of change during diﬀerent relapse prevention strategies.
Participants (N = 45) will be randomly allocated to either continuing
ADM (n = 15), continuing ADM combined with an eight-session PCT
(n = 15), or tapering of ADM in combination with PCT (n = 15).
Current and previous depressive episodes will be monitored using tel-
ephonic interviews at the start of the study and after three, nine, 15,
and 24 months. The ESM procedure will take place during the ﬁrst eight
weeks of the study (parallel to the PCT training for those individuals
randomly allocated to receive PCT). Data of a never depressed control
group will be collected.
The addition of ESM to the RCT ‘Disrupting the rhythm of depres-
sion’ (Netherlands Trial Register: NTR1907) was approved by the
medical ethical board of the University Medical Center Groningen
(METc 2009/158). Ethical approval for including never depressed in-
dividuals has been obtained from the University of Groningen Ethical
Committee of the Psychology Department (ppo-014-043). This study is
funded by ZonMW: The Netherlands Association for Health Research
and Development (171002401 and OOG Grant 100002035) and by
NWO, the Netherlands Organization for Scientiﬁc Research
(022.003.038).
3.1. Sample
The previously depressed sample will be recruited parallel to the
three-armed RCT ‘Disrupting the rhythm of depression’ [31]. To be
included, participants have to be diagnosed with remitted, recurrent
MDD, as deﬁned according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM–IV) and assessed by trained interviewers using
the Structured Clinical Interview for DSM–IV disorders (SCID-I) [61].
Further inclusion criteria are a current score of ≤10 on the Hamilton
Rating Scale for Depression (HRSD) [62], and use of continuation ADM
in the last six months. Exclusion criteria are current mania or hypo-
mania or a history of bipolar illness, any psychotic disorder (current
and previous), organic brain damage, alcohol or drug dependency/
abuse, and predominant anxiety disorder. After inclusion, participants
will be randomly allocated to one of the three arms of the study.
The matched never depressed sample will be recruited via adver-
tisements on social media, posters, and word of mouth. Participants will
be selected to match the previously depressed sample on age, gender,
and educational level. Exclusion criteria are current or previous de-
pressive episodes as assessed with the SCID-I, and use of ADM.
Participants will receive a 10 euro gift certiﬁcate.
3.2. Procedure
The procedure as described in the trial protocol of the RCT [31] will
be followed, with the adjustments that PCT will be administered in-
dividually rather than in groups, and the addition of the ESM proce-
dure. Participants randomized to a PCT condition will receive eight
weekly sessions of individual PCT, administered by trained psycholo-
gists using the treatment manual [63]. Participants randomized to ADM
continuation (with or without PCT) will be advised to continue ADM in
line with leading clinical guidelines [32,64] and their general practi-
tioner or psychiatrist will also be informed. For participants rando-
mized to the tapering condition, the instruction will be to gradually
taper ADM in four weeks guided by their general practitioner or psy-
chiatrist, who will also be informed and advised.
3.3. Experience sampling method
The experience sampling app ‘Imagine your mood’ has been devel-
oped and programmed using TEMPEST software [65]. This app will
enable participants to ﬁll out the questionnaires on their own smart-
phone. If needed, a research-smartphone will be made available to
participants. The questionnaire includes a section on aﬀect and emo-
tions, followed by questions about cognitions and imagery, and ﬁnally a
section on activities. The application has been programmed to set
triggers for questionnaires ten times a day, three days a week (on
Thursdays, Fridays, and Saturdays), for eight weeks, resulting in a
maximum of 240 responses. The triggers are set semi-randomly, with
one trigger per 90-minute interval between the hours of 7.30 and 22.30,
and a minimum of 30 min between triggers.
During an approximately one-hour face-to-face brieﬁng, a trained
assistant will install the app on the smartphone of a participant, explain
the ESM procedure, elucidate the more diﬃcult concepts, help practice
the questionnaire, and answer any questions. Participants will be in-
structed to respond to a trigger as soon as possible, and answer the
questionnaire about the moment just before the trigger. Participants
will not be informed about the ﬁve-minute time limit that is set on the
questionnaire; they will be instructed that they are too late if the
questionnaire is no longer available. Participants will receive weekly
brief structured telephonic interviews to monitor the functionality and
use of the ‘Imagine your mood’ app. Participants will be invited to
contact their assistant for questions or technical diﬃculties. An over-
view of assessments is provided in Table 1.
3.4. Measures
To examine the research questions, the following measures will be
used.
3.4.1. Aﬀect
Momentary mood will be assessed with the mood scale [59]. Par-
ticipants rated the question “at the moment, I feel…” on a VAS ranging
from happy (0) to sad (100).
Adjectives to assess positive aﬀect and negative aﬀect were selected
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based on previous research [66] and the adjectives described in the
diagnostic criteria of a depressive episode [57], and discussions in our
research team. Ratings of the adjectives (on a 0–100 VAS) will be
averaged to a positive aﬀect (cheerful, enthusiastic, hopeful, content, en-
ergetic) and a negative aﬀect (anxious, angry, lonely, irritated, down,
suspicious, helpless, guilty, insecure) scale per moment per individual.
3.4.2. Degree of mental imagery
First, participants will be presented with instructions to identify
what they had in mind just before the trigger, i.e. their mental re-
presentation. In the brieﬁng, participants will be familiarized with this
procedure and instructed as follows “you (almost) always have something
in mind. Please take your time to recall what you had in mind just before the
trigger. If you do not remember what you had in mind just before the trigger,
please select the most recent thing you had in mind that you can remember.”
Participants will receive the following information about mental
imagery: “Sometimes you see things in mind, while you do not see those with
your eyes at that moment. For example, when you recall a memory or when
you imagine yourself doing something in the future. You can also experience
this with other sensory modalities. With hearing, for example, when you
have a song in your head. Can you for example remember the last time you
did groceries, or that you were on vacation? What do you see in your mind's
eye? Can you hear the sounds in the memory? Or feel a physical sensation,
like the sun on your face or perhaps an itch?”
Participants will rate the degree of visual mental imagery answering
the question “I see it in my mind's eye” on a VAS running from 0 to 100.
Non-visual mental imagery will be assessed with the questions “(it) is
an auditory sensation,” and “(it) is a physical sensation.”
Participants will rate the valence of their mental representation on a
VAS ranging from negative (0) to positive (100).
3.4.3. Follow-up measures (for previously depressed participants only)
The primary outcome measure of the ‘Disrupting the rhythm of
depression’ RCT [31] is the time-related proportion of depressive re-
lapse as assessed using the SCID-I at three, nine, 15 and 24 months
(current depressive symptomatology and previous three, six, or nine
months). Severity of depressive symptomatology at all time points will
be assessed with the HRSD.
3.4.4. Successful tapering of ADM (for previously depressed participants
only)
The ADM dose will be assessed during the weekly telephonic in-
terviews. Both a lenient and a stringent operationalization of successful
tapering will be used. The lenient operationalization entails an ADM
dose reduction of ≥50%, whereas the stringent operationalization ad-
ditionally requires that the individual does not relapse into a depressive
episode.
The following measures will be included for hypothesis-generating
purposes.
3.4.5. Impact of ESM
Additional measures will be included in the questionnaire to explore
whether responding to the ‘Imagine your mood’ app may have an im-
pact on aﬀect. After reporting on their emotions and mental re-
presentation just before the beep, participants will be asked to assess
their current mood on a VAS ranging from happy (0) to sad (100) and
their current anxiety (0–100). Furthermore, at the end of the ques-
tionnaire participants will be asked to what degree ﬁlling out the
questionnaire had bothered them (on a 0–100 VAS).
3.4.6. Mental representation
For exploratory reasons, several other aspects of the selected mental
representation (what I have in mind …) will be assessed (on 0–100
VASs). Concrete verbal thinking will be assessed with the questions “I
think in words” and “I think in sentences.” Abstract verbal thinking
(worry/rumination) has been included in the questionnaire using the
following items: “I'm worrying,” “I think about my feelings,” “I wonder
why I react the way I do,” and “I analyze the meaning of my feelings.”
The intrusiveness will be assessed using the adjectives derived from
Brewin et al. [67]: “distressing,” “uncontrollable,” ”interfering,” and
“vivid.”
Additionally, participants will be asked to rate the degree to which
the mental representation is personally relevant (0 = not personally
relevant, 100 = personally relevant), whether it refers to “the distant
past” (0) or “the far future” (100), and whether they experience the
tendency to approach (0) or avoid (100) what they had in mind.
Momentary avoidance tendencies will be calculated by averaging this
last rating with the rating on the question as to what degree they ex-
perience the tendency to approach (0) or avoid (100) their emotions.
3.4.7. Physical complaints
Physical complaints will be assessed with the questions “I feel tired”
and the recoded “I feel ﬁt physically” (on 0–100 VASs).
3.4.8. Activities
Participants will be asked to identify their current activity and rate
this activity on the following scales: “I like doing this,” “this activity
requires eﬀort,” “I feel I'm being active” (on 0–100 VASs) and select the
category to which the activity belongs.
Participants will be asked to select the most important previous ac-
tivity (stressor or event) in the two hours before the trigger, rate this
activity on a VAS that runs from “unpleasant” (0) to “pleasant” (100),
and select the category to which the activity belonged.
Finally, participants will be invited to identify the most important
future event in the next two hours, answer the question “I'm not looking
forward to it” (lack of anticipatory pleasure) on a 0–100 VAS and select
the category to which the event belongs.
3.5. Analyses
Diﬀerent analyses will be used for the variety of research questions.
The experience sampling data represent repeated measurement within
individuals, and this nested structure will be taken into account in all
the analyses. An important assumption in many time series analyses is
stationarity (i.e. that processes do not change over time). This as-
sumption will be handled either by removing the trends from the data,
or by using analyses that do not assume stationarity. Baseline char-
acteristics of never depressed and previously depressed individuals will
be compared to examine whether confounding factors may play a role.
First, individual diﬀerences in aﬀect will be explored. For ex-
amining whether aﬀective changes may signal future relapse, time-
varying autoregressive time series models [68] will be ﬁtted for each
individual. These models allow for the processes in the data to change
over time and are excellently suited for examining the presence of such
time-varying processes within individuals. Speciﬁcally, the presence of
changes in the intercept and autoregressive parameter (see Formula
Table 1
Overview of assessments.
Instrument Baseline ESM study period Follow-up period (in months)
3 9 15 24
SCID-I + * * * *
HRSD + * * * *
ESM + (8 weeks)
Weekly calls + (8 weeks)
Note. SCID-I = Structured Clinical Interview for DSM-IV disorders, HRSD = Hamilton
Rating Scale for Depression, ESM = Experience sampling methodology, + Both pre-
viously depressed and never depressed individuals, * Previously depressed individuals
only.
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(1)) are examined to assess the presence of change in mean level and
inertia of negative aﬀect. These analyses will be performed both in
previously depressed and in never depressed individuals, to examine
whether individual aﬀective trajectories are speciﬁc to depressive re-
lapse.
= + +−Negative affect β β Negative affect ε .t t t t t0, 1, 1 (1)
Second, how imagery-based processing may contribute to aﬀective
disturbances in daily life will be explored using mixed linear models.
Trends over time will be removed from the data to prevent spurious
correlations and data will be person-mean centered. Post-hoc analyses
will be used to examine whether ﬁndings hold in both the previously
depressed and never depressed groups.
Third, it will be examined whether early aﬀective responses can
predict successful tapering of ADM by analyzing the data of the ﬁrst two
weeks in the previously depressed participants randomized to PCT
while tapering ADM. A bivariate vector-autoregressive Bayesian dy-
namic model [69] will be performed to model the time structure of the
data. More speciﬁcally, the mean levels, inertia, and variability will be
assessed. Subsequently, it will be examined how these measures of af-
fect and aﬀect dynamics are related to successful tapering of ADM.
Finally, network modeling will be used in two exploratory ways to
examine whether relapse prevention strategies in the three treatment
arms of the RCT diﬀerentially target the network of dynamic interac-
tions between cognitive, behavioral, and aﬀective states. First, group-
level network analyses will be used to investigate potential diﬀerences
in network architecture (e.g. centrality) between the three arms of the
trial. Second, as intra-individual network modeling in the context of
clinical trial data is still in the developing phase, it will be explored to
which extent changes in network architecture over time within in-
dividuals can be assessed.
4. Discussion
Both continuation of ADM and psychological interventions can re-
duce the risk of relapse in previously depressed individuals, but
knowledge informing what works best for whom is needed. This micro-
trial aims to explore how ESM may inform personalized relapse pre-
vention strategies. Emotions, mental imagery, cognitions, and beha-
viors will be repeatedly assessed using the smartphone application
‘Imagine your mood’ in a group of previously depressed individuals.
The data will be collected alongside a three-armed RCT ‘Disrupting the
rhythm of depression’ that investigates what works best in preventing
relapse (i.e. continuation of ADM, the combination of ADM with PCT,
or tapering ADM combined with PCT). Additionally, a control group of
matched never depressed individuals will be included. The relatively
limited number of participants included in this micro-trial (45 pre-
viously depressed and 15 matched never depressed individuals) will be
compensated by the great number of repeated assessments (max 240)
within each individual.
In sum, this study will explore four routes to furthering personalized
relapse prevention using ESM: individual diﬀerences in vulnerability
for relapse, processes underlying aﬀective vulnerability, within-in-
dividual change while undergoing diﬀerent relapse prevention strate-
gies and how these relate to successful tapering and prevention of re-
lapse, and diﬀerential eﬀects of relapse prevention strategies. These
four approaches may be interdependent. For example, examining how
cognitive mechanisms contribute to aﬀective vulnerability may be
complemented by an understanding of how mechanisms are targeted by
diﬀerent relapse prevention strategies. The data may help unravel the
role of individual diﬀerences in depressive relapse while undergoing
diﬀerent relapse prevention strategies. This may provide novel in-
formation on processes of change as a ﬁrst step towards improving the
protective eﬀect of relapse prevention strategies by tailoring them to
individual needs using experience sampling methodology.
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The addition of ESM to the RCT “Disrupting the rhythm of depres-
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